Literature DB >> 15035965

Earlier management of subjects who are prone to hypertension and diabetes mellitus.

Hiromi Rakugi1, Toshio Ogihara.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15035965     DOI： 10.1007/s11892-004-0058-9

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


× No keyword cloud information.
  15 in total

1.  Angiotensin blockade prevents type 2 diabetes by formation of fat cells.

Authors:  Arya M Sharma; Jürgen Janke; Kerstin Gorzelniak; Stefan Engeli; Friedrich C Luft
Journal:  Hypertension       Date:  2002-11       Impact factor: 10.190

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Utility of HbA(1c) levels for diabetes case finding in hospitalized patients with hyperglycemia.

Authors:  Laura S Greci; Mala Kailasam; Samir Malkani; David L Katz; Ilja Hulinsky; Ramin Ahmadi; Haq Nawaz
Journal:  Diabetes Care       Date:  2003-04       Impact factor: 19.112

4.  Insulin resistance and cardiovascular complications in patients with essential hypertension.

Authors:  K Kamide; M Nagano; N Nakano; Y Yo; R Kobayashi; H Rakugi; J Higaki; T Ogihara
Journal:  Am J Hypertens       Date:  1996-12       Impact factor: 2.689

5.  Insulin resistance is related to silent cerebral infarction in patients with essential hypertension.

Authors:  K Kamide; H Rakugi; N Nakano; M Ohishi; Y Nakata; S Takami; T Katsuya; J Higaki; T Ogihara
Journal:  Am J Hypertens       Date:  1997-11       Impact factor: 2.689

6.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

7.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  Risk factor clustering in patients with hypertension and non-insulin-dependent diabetes mellitus. The Skaraborg Hypertension Project.

Authors:  E Bøg-Hansen; U Lindblad; K Bengtsson; J Ranstam; A Melander; L Råstam
Journal:  J Intern Med       Date:  1998-03       Impact factor: 8.989

9.  2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.

Authors: 
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

10.  Insulin-mediated growth in aortic smooth muscle and the vascular renin-angiotensin system.

Authors:  K Kamide; M T Hori; J H Zhu; J D Barrett; P Eggena; M L Tuck
Journal:  Hypertension       Date:  1998-09       Impact factor: 10.190
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.